Drugs / MK-3281
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00635804 | Feb 2008 → Dec 2009 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-3281 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00635804 ↗ |
| Modality | Small molecule | — CHEMBL1233524 ↗ |
| Route | Oral | “MK-3281 orally BID” NCT00635804 ↗ |